Hepatitis C in Prison: Study of Screening and Rapid Treatment (HEPAPRIS)
Reason given: No patient eligible
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT05649202
- Record updated
- 6 May 2026
- Original description
Due to the high prevalence of HCV in prison and the risk of transmission between inmates, the management of hepatitis C and its treatment must be optimal following the recommendations of AFEF.Read full original descriptionShow less
Hepatitis C in Prison: Study of Rapid Diagnosis and Treatment
Due to the high prevalence of HCV in prison and the risk of transmission between inmates, the management of hepatitis C and its treatment must be optimal following the recommendations of AFEF.
The purpose of this study is to assess the treatment starting delay from the date of incarceration of inmates with chronic HCV infection (hepatitis C).
Inclusion: Adult patient (>/= 18 years old),; Persons detained at the Paris-La Santé Penitentiary Center (CPPLS) coming from the state of freedom or transferred from another penitentiary establishment; Serology HCV positive.
Exclusion: Major psychiatric disorders with loss of discernment; Persons under guardianship or curatorship; Persons not affiliated to a social security scheme.